Cross-Border Impact Ventures

OXcan is a startup that focuses on early detection of lung cancer using advanced machine learning and liquid biopsy technologies. The company has developed an artificial intelligence-based healthcare platform that identifies cancer by analyzing targeted blood tests. This platform detects cancer-related materials released into the bloodstream, allowing for cost-effective and routine screening. By evaluating multidimensional liquid biopsy results, which include DNA, proteins, epigenetic markers, and patient medical histories, OXcan enables healthcare providers to achieve early cancer detection and implement curative treatment strategies.

OncoLens is a healthcare technology company that develops software solutions aimed at improving cancer care coordination and treatment planning. Their primary product is a HIPAA-compliant, mobile and web-based platform that integrates diverse data sets, oncology care teams, and stakeholders onto a single platform. This platform facilitates multi-disciplinary treatment planning, tumor board discussions, life-science commercial efforts, clinical trials enrollment, and payor authorizations. It also incorporates AI-driven clinical decision support capabilities to enhance the quality of cancer patient care.

Raydiant Oximetry, Inc. is a medical device company established in 2015 and headquartered in Mountain View, California. The company specializes in the development of a low-cost, non-invasive device that monitors fetal oxygen levels during labor, with the aim of improving health outcomes for mothers and their babies. By providing real-time data on fetal oxygenation, Raydiant Oximetry's technology seeks to enhance patient care, reduce the occurrence of unnecessary cesarean sections, and lower healthcare costs associated with childbirth. The company's innovations are designed to address potential birth injuries and minimize over-intervention in the delivery process, ultimately striving to improve the overall experience and safety of childbirth.

Axena Health is a company focused on improving the lives of women with pelvic floor disorders through digital technology. Its flagship product, Leva Pelvic Health System, is a prescription digital therapeutic offering at-home treatment for urinary and chronic fecal incontinence in women.

OncoLens is a healthcare technology company that develops software solutions aimed at improving cancer care coordination and treatment planning. Their primary product is a HIPAA-compliant, mobile and web-based platform that integrates diverse data sets, oncology care teams, and stakeholders onto a single platform. This platform facilitates multi-disciplinary treatment planning, tumor board discussions, life-science commercial efforts, clinical trials enrollment, and payor authorizations. It also incorporates AI-driven clinical decision support capabilities to enhance the quality of cancer patient care.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Founded in 2017, Daye is a London-based company dedicated to improving women's gynecological health. It manufactures and markets innovative tampon products, including CBD-infused options for period pain relief, and offers an at-home vaginal microbiome screening kit to detect infections and microbiome disruptions.

Macro-Eyes, Inc. is a machine learning company focused on enhancing access to healthcare through its innovative solutions. Its primary product, Sibyl, employs artificial intelligence for intelligent patient scheduling, which has shown a capability to improve patient utilization by 15%, enabling healthcare providers to see more patients without extending clinical hours. This technology is built on extensive research and deployment of AI for clinical decision support at prominent institutions, including Stanford University and major health systems in the United States. The company has garnered support from the Bill & Melinda Gates Foundation to develop a predictive supply chain for health, aimed at optimizing resource allocation at individual health facilities and pharmacies to prevent stock-outs and reduce waste. Additionally, Macro-Eyes is collaborating with the California Primary Care Association to implement Sibyl across 1,800 health facilities, thereby furthering its mission to increase access to life-saving care.